Which treatment for alcohol dependence: naltrexone, acamprosate and/or behavioural intervention?

Abstract:

:Alcoholism is the third leading cause of preventable mortality and morbidity in the US. In the COMBINE (Combined Pharmacotherapies and Behavioural Interventions) study, the co-primary end points were the percentage of days abstinent and the time to first heavy drinking day after 16 weeks, and 1 year. The biggest difference observed in COMBINE was that seen between combined behavioural intervention (CBI; percentage of abstinent days = 66.6%) and CBI and medical management with placebos (79.8%). This illustrated a major effect of the medical management of nine sessions and/or the placebo pills. Acamprosate had no effect alone or in combination with naltrexone. At 16 weeks with medical management, there were 75.1% of the patients who were abstinent for placebos, and this was improved by naltrexone, CBI, and naltrexone with CBI (80.6, 78.2 and 77.1%, respectively). There was a follow up after 1 year, which showed that, with medical management, the amount of those who were abstinent for placebos was 61.4%, and this was improved by naltrexone, CBI, and naltrexone with CBI (66.2, 66.6 and 67.3%, respectively), but this improvement no longer reached statistical significance. After 1 year, there was no difference between groups in the overall frequency of hospitalisation, emergency treatment for alcohol problems, use of medication for drinking or emotional problems and detoxification. Being part of a study for alcohol dependence is known to increase the percentage of abstinent days. In COMBINE, this percentage was high in the group having medical management and placebo pills, and naltrexone or additional behavioural therapy only had modest additional effects.

authors

Doggrell SA

doi

10.1517/14656566.7.15.2169

subject

Has Abstract

pub_date

2006-10-01 00:00:00

pages

2169-73

issue

15

eissn

1465-6566

issn

1744-7666

journal_volume

7

pub_type

杂志文章
  • Antimicrobial treatment of anaerobic infections.

    abstract:INTRODUCTION:Anaerobes are the most predominant components of normal human skin and mucous membrane bacterial flora and are, therefore, a common cause of endogenous bacterial infections. Because of their fastidious nature, they are difficult to isolate from infectious sites and are often overlooked. Anaerobic infection...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.576672

    authors: Brook I

    更新日期:2011-08-01 00:00:00

  • The treatment of neoplastic meningitis.

    abstract::Neoplastic meningitis (NM) is a debilitating complication of cancer that occurs when tumour cells infiltrate the leptomeninges. Treatment often includes direct installation of chemotherapy into the cerebrospinal fluid either by lumbar puncture or the use of a ventricular reservoir, radiation therapy, systemic chemothe...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656566.5.9.1929

    authors: Armstrong TS,Gilbert MR

    更新日期:2004-09-01 00:00:00

  • Tamoxifen and the female reproductive tract.

    abstract::The use of tamoxifen among women with breast cancer or at high risk of the disease has greatly expanded over the past several decades. Tamoxifen has a complex effect on the female reproductive tract and several tamoxifen-associated changes have been described among tamoxifen users. These include endometrial thickening...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2.9.1399

    authors: Eltabbakh GH,Mount SL

    更新日期:2001-09-01 00:00:00

  • The treatment of Tourette's syndrome: current opinions.

    abstract::Correct education of the patient is one of the most important aspects in the treatment of Tourette's syndrome. Pharmacotherapy is often unsatisfactory and therefore should be limited to those patients who are significantly impaired. Therapy must be individualised and the most troublesome symptom should be targeted fir...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.3.7.899

    authors: Müller-Vahl KR

    更新日期:2002-07-01 00:00:00

  • Current approaches to therapy for vascular injury.

    abstract::Vascular injury is a ubiquitous phenomenon which can be both occult (such as with hyperlipidemia) and overt (such as with angioplasty). While the exact pathophysiology differs between acute and chronic atherosclerosis, both lesions can be mechanistically explained by the vasculature's exaggerated response to injury. P...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2.5.753

    authors: Selzman CH

    更新日期:2001-05-01 00:00:00

  • Several options for antiviral treatment trials in multiple sclerosis--but which targets should be selected?

    abstract::Involvement of viruses in the pathogenesis of multiple sclerosis (MS) is a long-lived hypothesis, which is has not yet been proven nor refuted. This is partly due to difficulties in the evaluation of diagnostic findings on persistent infections by common viruses such as herpesviruses and endogenous retroviruses. Progr...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.1.6.1087

    authors: Bergström T

    更新日期:2000-09-01 00:00:00

  • Eluxadoline for the treatment of diarrhoea-predominant irritable bowel syndrome.

    abstract:INTRODUCTION:Irritable bowel syndrome (IBS) treatment is challenging physicians because of its multifactorial physiopathology. In particular, abdominal pain and diarrhea management lack one unique effective pharmacological remedy. Opioid receptors, present in the central nervous system (CNS) and the enteric nervous sys...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2016.1182982

    authors: Scarpellini E,Laterza L,Ianiro G,Tack J,Abenavoli L,Gasbarrini A

    更新日期:2016-07-01 00:00:00

  • A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer.

    abstract::Following Huggins' original observation of the dependence of the prostate on androgens, testosterone suppression by either orchiectomy or oestrogen compounds (e.g., diethylstilbesterol [DES]) became the standard palliative treatment for advanced prostate cancer. Early studies showed testosterone suppression improved s...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.5.2.447

    authors: Perez-Marrero R,Tyler RC

    更新日期:2004-02-01 00:00:00

  • Treatment options for chronic myeloid leukemia.

    abstract:INTRODUCTION:The bcr-abl tyrosine kinase inhibitors (TKIs) are the cornerstone treatment for chronic myeloid leukemia (CML). However, there are many topics related to therapy that remain debated. AREAS COVERED:The aim of this paper is to give the reader a comprehensive review of how to treat CML at diagnosis, how to m...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.671296

    authors: Tanaka MF,Kantarjian H,Cortes J,Ohanian M,Jabbour E

    更新日期:2012-04-01 00:00:00

  • An economic commentary on the occurrence and control of HIV/AIDS in developing countries: special reference to India.

    abstract::HIV infection has a complex relationship with poverty, but affects both the rich and poor. HIV/AIDS represents the deadliest emergency and the greatest social, economic and health crisis of modern times. The HIV pandemic affects developed and developing countries differently, with up to 95% of new HIV infections now o...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 社论

    doi:10.1517/14656566.7.18.2447

    authors: Muniyandi M,Ramachandran R,Balasubramanian R

    更新日期:2006-12-01 00:00:00

  • Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012

    abstract:INTRODUCTION:Multiple sclerosis (MS) is an autoimmune neurodegenerative disease of the central nervous system involving inflammation, chronic demyelination and axonal loss. MS affects more than 2 million people worldwide. AREAS COVERED:This article aims to summarize the findings from two pivotal 2-year, randomized, do...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 评论,杂志文章

    doi:10.1517/14656566.2013.826190

    authors: Havrdova E,Hutchinson M,Kurukulasuriya NC,Raghupathi K,Sweetser MT,Dawson KT,Gold R

    更新日期:2013-10-01 00:00:00

  • Second line treatment options for pancreatic cancer.

    abstract:INTRODUCTION:Patients with advanced pancreatic cancer (APC) refractory to first-line therapy have a dismal prognosis and limited therapeutic options, with only one option consisting of nanoliposomal irinotecan in combination with fluorouracil and folinic acid which was approved by FDA based upon results of the phase II...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1369955

    authors: Passero FC Jr,Saif MW

    更新日期:2017-10-01 00:00:00

  • Indirect treatment comparison of the efficacy of patisiran and inotersen for hereditary transthyretin-mediated amyloidosis with polyneuropathy.

    abstract:INTRODUCTION:Patisiran and inotersen are two therapies approved for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy, a rapidly progressive disease with a substantial clinical burden. This analysis indirectly compares the efficacy of patisiran and inotersen on neuropathy and qu...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2020.1811850

    authors: Gorevic P,Franklin J,Chen J,Sajeev G,Wang JCH,Lin H

    更新日期:2021-01-01 00:00:00

  • Somatostatin analogues in the treatment of endocrine tumors of the gastrointestinal tract.

    abstract::Somatostatin and its long-acting analogues have been introduced for the treatment of endocrine tumours of the gastrointestinal tract as they have been shown to effectively control symptoms resulting from excessive hormone release in patients with carcinoid, Verner-Morrison and glucagonoma syndromes. This beneficial ef...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.3.6.643

    authors: Arnold R,Wied M,Behr TH

    更新日期:2002-06-01 00:00:00

  • Cost-effectiveness of widespread screening for Chlamydia trachomatis.

    abstract::Screening for sexually transmitted diseases is included in routine health care for several infectious agents in many western European countries. Current considerations on extensions of these programs include widespread screening strategies for Chlamydia trachomatis. In women, C. trachomatis infection may lead to seque...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.3.10.1443

    authors: Postma MJ,Welte R,Morré SA

    更新日期:2002-10-01 00:00:00

  • The pharmacogenetics of analgesia.

    abstract::Genomic variations influencing response to pharmacotherapy of pain are under investigation. Candidate genes such as (opioid)-receptors, transporters and other molecules important for pharmacotherapy are discussed. Drug metabolising enzymes represent a further major target of ongoing research in order to identify assoc...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.14.2235

    authors: Stamer UM,Stüber F

    更新日期:2007-10-01 00:00:00

  • Everolimus: preventing organ rejection in adult kidney transplant recipients.

    abstract:INTRODUCTION:Kidney transplantation is the treatment of choice for patients with end-stage renal failure, and their survival after transplantation is gradually improving. Everolimus (EVL) is a mammalian target of rapamycin inhibitor, providing a safe and effective immunosuppressive regime after kidney transplantation. ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.662955

    authors: Dantal J

    更新日期:2012-04-01 00:00:00

  • Pharmacotherapy of postpartum depression: an update.

    abstract:INTRODUCTION:Postpartum depression (PPD) is a common and serious illness that affects up to 14% of women in the first month after childbirth. We present an update on the pharmacologic treatment of PPD, although there continues to be a lack of large, randomized controlled trials (RCTs). AREAS COVERED:A review of the li...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.911842

    authors: Kim DR,Epperson CN,Weiss AR,Wisner KL

    更新日期:2014-06-01 00:00:00

  • Botulinum toxin for the treatment of cervical dystonia.

    abstract::Cervical dystonia (CD) manifests clinically through involuntary spasms of neck muscles, producing abnormal head and neck movements and postures, which is often associated with pain. CD is the most common form of focal dystonia presenting to movement disorders clinics. Chemodenervation with botulinum toxin (BTX) has be...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2.12.1985

    authors: Tintner R,Jankovic J

    更新日期:2001-12-01 00:00:00

  • An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma.

    abstract:INTRODUCTION:Hepatocellular carcinoma (HCC) is a frequent and severe complication of cirrhosis. Most HCC patients initially present with or progress to advanced stage disease and require systemic treatment. As hypervascularization is a major characteristic of HCC, antiangiogenic drugs have been tested. Areas covered: I...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1378346

    authors: Raoul JL,Gilabert M,Adhoute X,Edeline J

    更新日期:2017-10-01 00:00:00

  • Anti-thrombotic therapy in cancer patients.

    abstract::Primary and secondary prevention of venous thromboembolism (VTE) are the major roles of anti-thrombotic therapy in patients with cancer. Although the choices of pharmacological agents remain limited, low molecular weight heparins (LMWHs) offer important advantages over traditional anticoagulants. For prophylaxis in th...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.12.2213

    authors: Lee AY

    更新日期:2003-12-01 00:00:00

  • Current and Emerging Pharmacotherapy for Chronic Spontaneous Urticaria: A Focus on Non-biological Therapeutics.

    abstract:INTRODUCTION:Chronic spontaneous urticaria (CSU) refers to urticaria (wheals) or angioedema, which occur for a period of six weeks or longer without an apparent cause. The condition may impair the patient's quality of life. AREAS COVERED:Treatment for CSU is mainly symptomatic. Both AAAAI/ACAAI practice parameters and...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2020.1829593

    authors: Hon KL,Li JTS,Leung AKC,Lee V

    更新日期:2020-09-29 00:00:00

  • Pharmacoeconomic considerations in anticoagulant drug use.

    abstract::Anticoagulants are used for the prevention and treatment of venous thromboembolism and for the secondary prevention of stroke and myocardial infarction. The list of available anticoagulants includes unfractionated heparin, low molecular weight heparins, fondaparinux, warfarin and the direct thrombin inhibitors. Numero...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.7.8.989

    authors: Hawkins D,Huston SA

    更新日期:2006-06-01 00:00:00

  • Pharmacotherapeutic strategies for managing comorbid depression and diabetes.

    abstract::Introduction: The increasing prevalence of comorbid depression and diabetes exerts a heavy burden on global health. Co-occurrence of depression and diabetes is common, affecting 14% to 35.8% of patients with diabetes, leading to a higher mortality and morbidity rate, more micro- and macro-vascular diseases and more co...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1622090

    authors: Li HQ,Chi S,Dong Q,Yu JT

    更新日期:2019-09-01 00:00:00

  • Current and up-and-coming pharmacotherapy for obsessive-compulsive disorder in adults.

    abstract:INTRODUCTION:Only 40-60% of obsessive-compulsive patients respond to first line treatments, such as selective serotonin reuptake inhibitors (SSRIs) and cognitive-behavioral therapy. Several second-line treatments have been investigated in the last two decades, and most of them seem to work, at least in a subset of pati...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1528230

    authors: Grassi G,Pallanti S

    更新日期:2018-10-01 00:00:00

  • Oral healthcare for HIV-infected patients: an international perspective.

    abstract::The orofacial complications of HIV infection are diverse, include opportunistic infection and malignancy and in many instances are region specific. Although effective management strategies to treat HIV-associated oral disease have been developed in North America and Europe, the evidence base on which these rely remain...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.3.387

    authors: Hegarty AM,Chaudhry SI,Hodgson TA

    更新日期:2008-02-01 00:00:00

  • From dorzolamide 2%/timolol 0.5% to brinzolamide 1%/timolol 0.5% fixed combination: a 6-month, multicenter, open-label tolerability switch study.

    abstract:PURPOSE:To assess ocular surface status and tolerability after switching glaucoma patients from dorzolamide/timolol to brinzolamide/timolol fixed combination (FC). METHODS:Six-month, multicenter, open-label, prospective study that switched 72 patients from dorzolamide/timolol to brinzolamide/timolol FC. Intraocular pr...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1517/14656566.2011.589384

    authors: Rossi GC,Pasinetti GM,Sandolo F,Bordin M,Bianchi PE

    更新日期:2011-11-01 00:00:00

  • Tolterodine extended-release for overactive bladder.

    abstract::Overactive bladder (OAB) is a common problem. Affected individuals suffer decreased quality of life and productivity. The mainstay of pharmacological treatment of OAB is antimuscarinic agents. Tolterodine was the first antimuscarinic drug designed specifically for treating OAB. Compared with the immediate-release (IR)...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560903167965

    authors: Chung DE,Te AE

    更新日期:2009-09-01 00:00:00

  • Amifostine: chemotherapeutic and radiotherapeutic protective effects.

    abstract::Amifostine (Ethyoltrade mark, Alza Pharmaceuticals) is an inorganic thiophosphate cytoprotective agent known chemically as ethanethiol, 2-[3- aminopropyl)amino]dihydrogen phosphate. It is a prodrug of free thiol (WR-1065) that may act as a scavenger of free radicals generated in tissues exposed to cytotoxic drugs and ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2.3.479

    authors: Santini V

    更新日期:2001-03-01 00:00:00

  • Everolimus: an immunosuppressive agent in transplantation.

    abstract::Everolimus is a novel immunosuppressive agent related to sirolimus. It is a proliferation signal inhibitor with an improved pharmacokinetic profile and bioavailability compared with sirolimus. Everolimus has been shown to be as effective as mycophenolate mofetil in reducing acute rejection in renal transplantation. In...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.7.10.1347

    authors: Patel JK,Kobashigawa JA

    更新日期:2006-07-01 00:00:00